Atlas Trials

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

Clinical trial NCT06558214 · RECRUITING

Trial details

NCT number
NCT06558214
Sponsor
University of Florida
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2024-12-10
Primary completion
2029-10-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.